ESCO Technologies

ESCO Technologies is the kind of mid-cap industrial that institutional analysts cover only because it sits in the Russell 2000 — and yet has delivered the kind of stretch (174 USD to 290 USD in twelve months, a ~65% advance) that most flashy tech names did not manage in the same window. The story is three segments, all currently in tailwind mode at the same time.

The largest leg is Aerospace and Defense: specialty filtration for hydraulics and fuel systems on commercial and military airframes, miniature electro-explosive devices for ejection seats and missile arming, and precision-machined bushings and pins for landing gear and rotor heads. The customer concentration is exactly what you want — Boeing, Airbus, Lockheed, Northrop, Pratt & Whitney — and the backlog runs three years out. Boeing 737 MAX rate increases (planned 47/month by end-2026), F-35 sustainment ramps and Sikorsky/AW149 build cycles are the proximate drivers.

The second leg is Utility Solutions (the Aclara smart-meter and grid-management business, acquired from Hubbell in 2018). The IRA infrastructure money plus state-level grid-hardening mandates (Texas, California, Florida) drive a backlog now north of 1.3 billion USD — a multi-year tailwind that is genuinely visible rather than wishful.

The third leg is the NTS Test business, acquired in 2024 — a network of US EMC/RF compliance labs serving 5G, automotive electrification and defense radar. This is the segment driving the 33.5% reported revenue growth: NTS only annualized into the comp base in late 2025. Organic growth ex-acquisition is closer to 7-9% — important to keep in mind when you read the headline number.

Institutional ownership is heavily index-driven (Vanguard ~11%, BlackRock ~10%, State Street ~5% — the standard passive tilt for a Russell 2000 constituent) but the active-money names are interesting: FMR (Fidelity) at 8.2% with Will Danoff's Contrafund position adding through Q1/2026; T. Rowe Price Mid-Cap Growth sitting at 4.3% and steadily building since 2024; Wellington Management at 3.9% — concentrated in the small/mid-cap defense-exposure mandate.

The smarter signal is what is not there: no activist position, no notable short campaign and no significant insider selling beyond mechanical 10b5-1 plans. CEO Bryan Sayler exercised options in March 2026 but retained the underlying shares — a quiet vote of confidence after the run-up.

Short interest sits at just 2.96% of float with a short ratio of 1.45 — among the lowest in the industrial-mid-cap peer set. That is not a coiled-spring squeeze setup, but it does tell you that the bear case is thin enough that no professional desk is willing to size into it.

ESCO trades at forward P/E 31.6x, EV/EBITDA 26.2x and EV/revenue 6.3x — all multi-year highs and clearly in the premium-mid-cap-industrial bucket. PEG ratio of 1.67 against forward EPS growth of ~17% is the metric the bulls point to, suggesting growth still justifies the multiple. Bears will note that the same PEG framework was wrong at the 2021 peak (PEG 1.4 then preceded a 35% derating in 2022).

The cleaner valuation frame is sum-of-the-parts. A&D segment at 18x EBITDA (defense-component peer set) is worth ~3.8 billion USD; Utility Solutions at 15x EBITDA (smart-grid-tech peer set) is worth ~2.4 billion USD; NTS Test at 14x EBITDA (specialty testing-services peer set) is worth ~1.6 billion USD — total enterprise value of ~7.8 billion USD versus current EV of ~7.7 billion. The market is paying for what the businesses are worth in isolation; the upside requires synergy execution or multiple expansion in one of the three.

Free cash flow of 320 million USD against a market cap of 7.5 billion gives a 4.3% FCF yield — adequate but not cheap. Dividend yield of 0.11% is a rounding error; the capital return story is buybacks and accretive M&A, not income.

1. August 2026: Q3 FY2026 earnings — first quarter showing organic growth without the NTS acquisition tailwind
2. Q4 2026: US defense supplemental authorization vote — meaningful impact on A&D backlog visibility for FY2027-2029
3. November 2026: Investor Day — first major capital-allocation update since NTS integration completed

ESCO is the boring quality compounder that has rewarded everyone who held it patiently for the last decade — and that is precisely the trap. The 65% advance from the 52-week low has compressed almost all of the asymmetry. You are now paying premium multiples for a business that operates in three cyclical end markets at the top of their respective cycles.

My personal approach with names like this is to wait for the organic-growth-rate normalization that almost certainly comes in Q3/2026 — when the reported growth rate compresses from 33% to single digits and the multiple takes a 10-15% breather. That is the entry. Buying at current levels asks you to underwrite both continued growth and continued multiple expansion, which is two layers of optimism stacked. I would not short it — the backlog and the smart-buy ratings give it support — but I would not chase it either. Watch list, not buy list, until the Q3 print.